type 2 diabetes
type 2 diabetes
Overview
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, impaired glucose homeostasis, and a progressive decline in pancreatic β-cell function. This condition leads to elevated blood glucose levels and is associated with various complications, including cardiovascular disease, neuropathy, and kidney dysfunction. The pathophysiology of T2DM involves complex interactions between genetic predisposition, lifestyle factors, and environmental influences, such as diet and physical activity. Pharmacological interventions, including glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors, have been developed to improve glycemic control and mitigate the risk of associated complications.
Focus of Latest Publications
Recent publications on type 2 diabetes have focused heavily on prevention, risk prediction, and individualized management. Several studies examined lifestyle-related exposures and screening tools, including sugar-sweetened and non-sugar sweetened beverages and their substitution patterns, waist circumference and grip strength, daily step counts combined with polygenic risk, and a revised FINDRISC incorporating sociodemographic indicators. Other work explored whether data-driven thresholds from wearable device data, including continuous glucose monitor outputs, may outperform fixed cutoffs in diverse populations, with type 2 diabetes included among the comparison groups. Across these studies, the main emphasis was on improving risk stratification and identifying more informative predictors of incident disease.
A second cluster of publications addressed interventions aimed at weight loss, glycaemic improvement, and remission. These included a multicentre machine-learning model to predict postoperative body mass index trajectories and long-term type 2 diabetes remission after metabolic bariatric surgery, a fully subsidized behavioral weight management program for adults with type 2 diabetes or prediabetes, a culinary medicine intervention in patients with type 2 diabetes and elevated body mass index, and an integrated lifestyle intervention combining calorie-carbohydrate restriction with or without time-restricted feeding in the DIREM trial. A case series also described type 2 diabetes remission or glycaemic improvement in gynaecologic oncology patients undergoing an acute preoperative weight loss protocol. These publications collectively highlight growing interest in structured lifestyle and surgical approaches, as well as in predicting who is most likely to benefit.
Other studies examined biological, social, and health-system determinants of type 2 diabetes. One Mendelian randomisation analysis investigated causal associations between DNA methylation markers and type 2 diabetes in West African populations, while another study reported a U-shaped association between blood mtDNA copy number and incident type 2 diabetes. Health literacy profiles among people living with type 2 diabetes were characterized to inform tailored interventions, and socioeconomic deprivation was evaluated as an added predictor of diabetes development in youth with prediabetes. Additional work assessed the prevalence, diagnostic coverage, treatment, and glycaemic control of type 2 diabetes in Cambodia, and estimated the costs and health benefits of optimizing care for uncomplicated type 2 diabetes in Lagos, Nigeria.
Economic and implementation-focused studies also featured prominently. Investigators assessed the economic burden of type 2 diabetes management in France according to clinical characteristics, and another study evaluated the costs and benefits of optimizing care in a real-world setting in Nigeria. Together, these publications suggest that current research on type 2 diabetes is increasingly centered on precision prevention, remission-oriented interventions, and the practical challenges of delivering effective care across diverse populations and health systems.